<DOC>
	<DOC>NCT01414192</DOC>
	<brief_summary>This study is being done to provide valid data on the evolution of a cohort of French participants treated with ezetimibe, alone or in combination with a statin, to be used in simulation models for cardiovascular disease (CVD). Patterns of drug use, evolution of risk factors for CVD, cardiovascular morbidity and mortality, and goal attainment in low density lipoprotein cholesterol (LDL-C) levels over time will be analyzed.</brief_summary>
	<brief_title>A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Inclusion criteria: Resident of Continental France Treated by ezetimibe either as monotherapy (Ezetrol®), or coadministered with a statin or administered in a fixed combination of ezetimibe and simvastatin (Inegy®) Incident treatment with ezetimibe at the time of recruitment into the study Exclusion criteria: Unlikely to be followedup for the next 6 months after recruitment due to a planned change of residence Participating in a clinical trial Unable to read the information letter in French and/or unable to participate in the telephone interview in French</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>